Amisulpride versus other atypical antipsychotics for schizophrenia.

ABSTRACT:

Background

In many countries of the industrialised world second generation (atypical) antipsychotics have become first line drug treatments for people with schizophrenia. The question as to whether, and if so how much, the effects of the various second generation antipsychotics differ is a matter of debate. In this review we examine how the efficacy and tolerability of amisulpride differs from that of other second generation antipsychotics.

Objectives

To evaluate the effects of amisulpride compared with other atypical antipsychotics for people with schizophrenia and schizophrenia-like psychoses.

Search strategy

We searched the Cochrane Schizophrenia Group Trials Register (April 2007) which is based on regular searches of BIOSIS, CINAHL, EMBASE, MEDLINE and PsycINFO.

SUBMITTER: Komossa K 

PROVIDER: S-EPMC4164462 | biostudies-literature | 2010 Jan

REPOSITORIES: biostudies-literature